Prevalence and prognostic implications of myocardial injury in patients with influenza

Anna M Nordenskjöld 1,*, Niklas Johansson2, Erik Sunnefeldt1, Simon Athlin2, and Ole Fröbert1,3,4,5

1Department of Cardiology, Faculty of Medicine and Health, Örebro University, 70281 Örebro, Sweden; 2Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, 70281 Örebro, Sweden; 3Steno Diabetes Center Aarhus, Aarhus University Hospital, 8200 Aarhus N, Denmark; 4Department of Clinical Medicine, Faculty of Health, Aarhus University, 8000 Aarhus, Denmark; and 5Department of Clinical Pharmacology, Aarhus University Hospital, 8200 Aarhus N, Denmark

Received 12 April 2022; revised 1 June 2022; accepted 14 June 2022; online publish-ahead-of-print 8 August 2022

Handling Editor: Jonas Faxén

Aims

Influenza may cause myocardial injury and trigger acute cardiovascular events. The aim of this study was to investigate the prevalence and prognostic implications of elevated high-sensitivity cardiac troponin I (hs-cTnI) in patients with influenza.

Methods and results

In this prospective cohort study, we consecutively enrolled patients with influenza-like illness from two emergency departments in Sweden during three seasons of influenza, 2017–20. Ongoing influenza infection was diagnosed by polymerase chain reaction and blood samples were collected for later analysis of hs-cTnI. All patients were followed-up for a composite endpoint of major adverse cardiovascular events (MACE) including death, myocardial infarction, unstable angina, heart failure, atrial fibrillation, and stroke within 1 year. Of the 466 patients with influenza-like symptoms, 181 (39%) were positive for influenza. Fifty (28%) patients were hospitalized. High-sensitivity cTnI was elevated in 11 (6%) patients and 8 (4%) experienced MACE. In univariate analyses, MACE was associated with age [hazard ratio (HR): 1.14, 95% confidence interval (CI): 1.05–1.23], hypertension (HR: 5.56, 95%CI: 1.12–27.53), estimated glomerular filtration rate (HR: 0.94, 95%CI: 0.91–0.97), and elevated hs-cTnI (HR: 18.29, 95%CI: 4.57–73.24), N-terminal prohormone of brain natriuretic peptide (HR: 14.21, 95%CI: 1.75–115.5), hs-CRP (HR: 1.01, 95%CI: 1.00–1.02), and white blood cell count (HR: 1.12, 95%CI: 1.01–1.25). In multivariate analysis, elevated hs-cTnI was independently associated with MACE (HR: 4.96, 95%CI: 1.10–22.41).

Conclusion

The prevalence of elevated hs-cTnI is low in unselected patients with influenza. Elevated hs-cTnI was associated with poor prognosis. A limitation is that the estimated associations are uncertain due to few events.

* Corresponding author. Tel: +46 19 602 54 05, Fax: +46 19 602 54 38, Email: anna.nordenskjold@regionorebrolan.se

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Background

Annual epidemics of influenza are estimated to result in 3–5 million cases of serious disease and 290 000–650 000 respiratory deaths worldwide. Although influenza is characterized predominantly by respiratory manifestations, myocarditis, and exacerbation of underlying chronic cardiac diseases, such as congestive heart failure and atrial fibrillation, are not uncommon. In addition, evidence has suggested that influenza may be a cause of acute myocardial injury and a trigger of acute cardiovascular events.

Retrospective studies, both case-control and self-controlled case-series, have demonstrated that patients who test positive for influenza are at increased risks of acute myocardial infarction (MI) and stroke. Moreover, concomitant influenza was found to negatively affect the short-term prognosis of patients with MI. Protection from influenza has been reported to improve prognosis in patients with MI, and a recent placebo-controlled trial showed that influenza vaccination following MI reduces future cardiovascular events.

Myocardial injury is defined as the detection of an elevated cardiac troponin (cTn) above the 99th percentile upper reference limit and the injury is considered acute if there is a rise and/or fall of cTn values. High-sensitivity immunoassays to measure the concentrations of cTn (hs-cTn) are recommended to detect myocardial injury, regardless of whether the underlying mechanism is ischaemic or non-ischaemic.

To date, only a few studies have measured hs-cTn in patients with influenza, with these studies showing that the prevalence of troponin positivity ranges widely and is dependent on the cohort studied. However, three recent studies have reported that increased hs-cTn concentrations were associated with acute cardiac events and death within 30 days.

Prospective studies assessing the prevalence of elevated hs-cTn in unselected cohorts and the association of elevated hs-cTn with major adverse cardiovascular events (MACE) are scarce. Therefore, the present study was designed to evaluate the prevalence of elevated high-sensitivity cTn (hs-cTn) and other cardiac and inflammatory markers in patients with laboratory-confirmed influenza, and to investigate the prognostic implication of elevated hs-cTn on MACE in these patients.

Methods

Study design and participants

This prospective cohort study conducted in Region Örebro County, Sweden, included patients aged ≥18 years who presented with influenza-like symptoms to the emergency departments (EDs) of Örebro...
University Hospital and Karlskoga County Hospital during the 2017/2018, 2018/2019, and 2019/2020 influenza seasons. The annual influenza season is defined as occurring between October 1 and April 30. Recruitment of patients during the 2019/2020 influenza season was terminated on 17 February 2020, due to the developing Coronavirus disease 2019 (COVID-19) pandemic.

All patients presenting with influenza-like illness at the EDs and who, due to a strong clinical suspicion of ongoing influenza illness were tested using reverse transcription polymerase chain reaction (RT-PCR) assays, were considered for inclusion. Written informed consent was required for inclusion. The exclusion criteria included an inability to provide informed consent, age <18 years and ongoing symptoms or findings indicating an acute coronary syndrome, pulmonary oedema, haemodynamically significant arrhythmia, or acute stroke.

Data on medical history, vaccination status, duration of illness, and clinical symptoms were collected from participants using questionnaires. An electrocardiogram (ECG) was recorded, and a nasopharyngeal swab was collected for RT-PCR analyses of influenza A and influenza B (Simplexa Flu A/B & RSV, Focus Diagnostics, Cypress, CA, USA). Blood samples were obtained directly after inclusion, at the ED, for subsequent analysis of hs-cTnI and other biomarkers. Plasma was collected in EDTA-containing tubes and stored at −70°C until analysis. Medical charts were consulted 1 year after inclusion to determine the incidence of MACE, defined as a composite of all-cause death, MI, hospitalization due to heart failure, unstable angina, atrial fibrillation, and stroke. The prevalence of myocarditis, other arrhythmias, and Takotsubo syndrome was also recorded.

Previous and later measurements of hs-cTnI values were also noted during the review of medical charts.

Patients with RT-PCR confirmed influenza were defined as the cases and patients who tested negative for influenza served as controls (Figure 1).

The study was performed in accordance with the Declaration of Helsinki and was approved by the Regional Ethical Review Board of Uppsala (2017/220). This trial is registered at www.clinicaltrials.gov: as NCT03339180.

Figure 1  Study cohort. A total of 466 individuals were included, 181 with confirmed influenza, and 285 without confirmed influenza.
Cardiac biomarkers
High-sensitivity cTnI was measured using the hs-cTnI-Centaur assay (ADVIA Centaur TNI-H, Siemens Healthcare), which has been reported by the manufacturer of having a population 99th percentile concentration (both sexes) of 47 ng/L with a corresponding coefficient of variation <5%. The sex-adjusted 99th percentiles for men and women are 57 and 37 ng/L, respectively.

N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was measured using the NT-proBNP-Cenatur assay (ADVIA Centaur PBNP-analysis, Siemens Healthcare), with cutoffs of 125 and 450 pg/mL for individuals aged <75 years old and >75 years, respectively, as determined by the manufacturer.

Outcome definitions
Baseline information was obtained from patients at inclusion and from medical charts.

Myocardial injury was defined as the detection of a value of hs-cTnI above the 99th percentile upper reference limit. If the review of medical charts revealed earlier or later clinically motivated single or repeated measurements of hs-cTnI, these values were compared with the hs-cTnI value measured at inclusion and the injury was considered acute if there was a rise and/or fall of cTnI values.

Causes of death 1-year after patient inclusion were determined based on International Statistical Classification of Diseases and Related Health Problems, (ICD-10 codes) recorded in medical charts or death certificates. Myocardial infarction was defined as ICD codes I21 and I22, unstable angina as ICD code I20, heart failure as ICD code I50, myocarditis as ICD codes I40 and I41, stroke as ICD code I63, and atrial fibrillation as ICD code I48. Event adjudication was not performed.

Primary and secondary endpoints and endpoint definitions
The primary endpoint was defined as the prevalence of increased hs-cTnI concentrations at the time of inclusion. High-sensitivity cTnI values above the sex-specific 99th percentiles were considered elevated. The secondary endpoint was defined as the time to a composite endpoint of MACE, including all-cause death, admission for MI, unstable angina, heart failure, atrial fibrillation, and stroke.

Statistical analyses
Normally distributed continuous variables are presented as mean ± standard deviation (SD), and non-normally distributed continuous variables as median and inter-quartile range (IQR). Differences between cases controls were assessed by unpaired t-tests on original scale or log scale as appropriate. Ordinal variables were assessed with $\chi^2$ tests for trend or Mann–Whitney U tests, and differences between proportions were evaluated by Pearson’s $\chi^2$ test or Fisher’s exact test, as appropriate. Two-sided P-values < 0.05 were considered statistically significant, with all estimates presented with their 95% confidence intervals (CIs). A small number of missing data did affect some of the other variables and numbers are reported in Table 1. For individuals in the influenza group with missing data in categorical variables these were imputed into the largest category and missing data in continuous variables were imputed as the mean or median value as appropriate. Tables 2 and 3 include imputed data.

Clinical characteristics associated with MACE were evaluated by univariate and multivariate Cox regression analyses. All factors associated with MACE on univariate analyses with a P < 0.05 were included in the multivariate model; these included age, hypertension, elevated hs-cTnI, elevated NT-proBNP, estimated glomerular filtration rate, hs-CRP concentration, and white blood cell (WBC) count. In multivariable analysis, hs-cTnI was used as a dichotomous variable, with a cutoff at the 99th percentile, to adjust for sex differences. Due to the low number of events (<10) and comparatively large number of exposures stepwise procedures with both forward and backward analyses were used to ascertain the results further. Hazard ratios (HRs) and their corresponding 95% CI are reported. The association between elevated hs-cTnI and MACE was also evaluated by log-rank test.

High-sensitivity cardiac troponin I was regarded as both a continuous and a categorical variable, with concentrations ≥37 ng/L for men and ≥37 ng/L for women considered elevated. NT-proBNP was also regarded as both a continuous and a categorical variable, with concentrations ≥300 pg/mL considered elevated in the acute setting.

All statistical tests were two-tailed and P < 0.05 was regarded as statistically significant. All statistical analyses were performed using the Predictive Analytical SoftWare (PASW statistics 17.03) programme (SPSS Inc, Chicago, IL, USA).

Results
Of the 466 patients who presented to the EDs during three influenza seasons, 181 (39%) tested positive for influenza, including 94 (52%) who were positive for influenza A and 87 (48%) who were positive for influenza B. Both patients with and without influenza had influenza-like symptoms for a median 4 days before inclusion. There was no difference in gender between groups. Patients with influenza were significantly younger, had a higher maximum body temperature, and had a lower rate of previous heart failure than patients without influenza (Table 1). In addition, estimated glomerular filtration rate was higher, concentrations of hs-cTnI, NT-proBNP, and hs-CRP were lower; WBC, neutrophil, lymphocyte, and platelets counts were lower; and erythrocyte sedimentation rate was lower in patients with than without influenza (Table 1).

Prevalence of elevated high-sensitivity cardiac troponin I
Of the 466 patients in the entire cohort, 43 (9%) had hs-cTnI concentrations above the sex-specific cutoff levels, including 11 (6%) of the 181 influenza positive and 32 (11%) of the 285 influenza negative patients.

Patients with confirmed influenza
Patients with influenza and elevated hs-cTnI were older, had higher NT-proBNP and hs-CRP concentrations, and more often had left bundle branch block compared with patients with influenza without elevated hs-cTnI (Table 2).

A total of 50 patients were hospitalized after ED evaluation, seven (14%) patients with elevated hs-cTnI and 43 (86%) patients without elevated hs-cTnI. All patients admitted to hospital were discharged alive after a median 3 days with influenza infection (ICD code J10) as primary diagnosis. No patients needed intensive care.

Patients with influenza and elevated high-sensitivity cardiac troponin I
Seven patients hospitalized for influenza had elevated hs-cTnI; of these, two (29%) were diagnosed with influenza A and five (71%) with influenza B. Elevation of hs-cTnI was acute in five patients and
|                          | Influenza 181 | No influenza 285 | P-value |
|--------------------------|--------------|-----------------|---------|
| **Demographics**         |              |                 |         |
| Female, n (%)            | 86 (47.5%)   | 146 (51.2%)     | 0.434   |
| Age, years (IQR)         | 55 (34–72)   | 61 (43–75)      | **0.030**|
| **Current infection**    |              |                 |         |
| Days with symptoms (IQR) | 4 (3–6)      | 4 (2–7)         | 0.316   |
| Maximal temperature, °C (±SD) | 39.2 (0.7) | 38.9 (1.0)      | **<0.001**|
| Recent vaccination, n (%) | 52/178 (29.2%) | 81/284 (28.5%) | 0.873   |
| **Risk factors**         |              |                 |         |
| BMI, kg/m², (IQR)        | 26.5 (23.5–29.6) | 26.8 (24.1–30.1) | 0.221   |
| Diabetes, n (%)          | 25/181 (13.8%) | 41/285 (14.4%)  | 0.863   |
| Hypertension, n (%)      | 65/181 (35.9%) | 113/283 (39.9%) | 0.385   |
| Hyperlipidaemia, n (%)   | 34/178 (19.1%) | 56/280 (20.0%)  | 0.813   |
| Smoking, n (%)           |              |                 |         |
| Never                    | 96 (53.0%)   | 141 (49.5%)     | 0.315   |
| Previous                 | 39 (21.5%)   | 83 (29.1%)      |         |
| Current                  | 23 (12.7%)   | 32 (11.2%)      |         |
| Unknown                  | 23 (12.7%)   | 29 (10.2%)      |         |
| **Medical history**      |              |                 |         |
| Asthma                   | 33/181 (18.2%) | 45/283 (15.9%)  | 0.531   |
| COPD                     | 12/181 (6.6%) | 26/283 (9.2%)   | 0.327   |
| Heart failure            | 9/179 (5.0%)  | 32/284 (11.2%)  | **0.021**|
| Myocardial infarction    | 14/181 (7.7%) | 28/283 (9.9%)   | 0.429   |
| PVD                      | 3/181 (1.7%)  | 9/280 (3.2%)    | 0.305   |
| Stroke                   | 7/181 (3.9%)  | 18/284 (6.3%)   | 0.249   |
| **Laboratory findings**  |              |                 |         |
| Hs-cTnI men, ng/L (IQR)  | 5.1 (2.7–17.6) | 8.9 (2.5–21.6)  | 0.125   |
| Hs-cTnI women, ng/L (IQR)| 3.1 (2.5–8.1) | 4.5 (2.5–14.0)  | 0.079   |
| Hs-cTnI, elevated (%)    | 11 (6.1%)    | 32 (11.2%)      | 0.861   |
| NT-proBNP, ng/L (IQR)    | 156 (57–549) | 259 (79–1407)   | **<0.001**|
| NT-proBNP, elevated (%)  | 62/179 (34.6%) | 131/282 (46.5%) | **0.012**|
| eGFR, mL/min/1.73 m² (%) | 85 (63–96)   | 76 (60–95)      | 0.036   |
| Hs-CRP mg/L (IQR)        | 33 (17–57)   | 57 (22–129)     | **<0.001**|
| WBC, x10³/L (±SD)        | 7.2 (3.5)    | 10.0 (4.2)      | **<0.001**|
| Neutrophils, x10³/L (±SD) | 5.4 (3.5)  | 7.8 (4.0)       | **<0.001**|
| Lymphocytes, x10³/L (±SD) | 1.0 (0.5)   | 1.2 (0.8)       | **0.006**|
| Platelets, x10³/L (±SD)  | 209 (72.1)   | 249 (98.3)      | **<0.001**|
| ESR, mm/h (IQR)          | 18 (9–31)    | 31 (15–53)      | **<0.001**|
| **ECG at presentation**  |              |                 |         |
| Heart rate b/min (±SD)   | 91 (19)      | 92 (19)         | 0.857   |
| Atrial fibrillation (%)  | 18/175 (10.3%) | 33/276 (12.0%)  | 0.579   |
| ST-elevation (%)         | 0            | 4/276 (1.4%)    | 0.161   |
| ST-depression (%)        | 8/175 (4.4%) | 14/276 (4.9%)   | 0.807   |
| LBBB (%)                 | 5/175 (2.8%) | 8/276 (2.8%)    | 0.977   |

Elevated hs-cTnI: men ≥57 ng/L and women ≥37 ng/L. Continuous variables with missing values, number (influenza/no influenza): days with symptoms 179/285, temperature 167/265, BMI 178/280, NT-proBNP 179/282, eGFR 174/280, hs-CRP 179/285, WBC 177/282, neutrophils 130/200, platelets 177/279, ESR 92/139, heart rate 175/276. BMI, body mass index; COPD, chronic obstructive pulmonary disease; ESR, erythrocyte sedimentation rate; ECG, electrocardiogram; PVD, peripheral vascular disease; HS-CRP, high-sensitivity C-reactive protein; LBBB, left bundle branch block; WBC, white blood cells. Bold P-values are significant (P < 0.05). *P-value: difference between patients with and without influenza.
suspected of being chronic in the other two, although an acute component could not be completely ruled out. Four patients with influenza and elevated hs-cTnI at inclusion were not hospitalized, with no further assessments documented in either hospital or outpatient-clinic charts. All were men aged between 27 and 74 years, with two diagnosed with influenza A and two diagnosed with influenza B. Electrocardiograms of all four showed sinus rhythm but no evidence of pathological ST-elevation or ST-depression. However, one individual had a left bundle branch block. A review of their medical charts found no evidence that their hs-cTnI concentrations had been measured before or after the event.

Table 2 Baseline demographic and clinical characteristics of patients with influenza, stratified by high-sensitivity cardiac troponin I elevation

|                          | Elevated hs-cTnI | No elevated hs-cTnI | P-value |
|--------------------------|------------------|--------------------|---------|
| Total, n                 | 11               | 170                |         |
| Demographics             |                  |                    |         |
| Female (%)               | 4 (36.4%)        | 82 (48.2%)         | 0.445   |
| Age, years (±IQR)        | 74 (56–87)       | 52 (34–71)         | 0.010   |
| Current infection        |                  |                    |         |
| Days with symptoms (IQR) | 4 (2–5)          | 4 (3–6)            | 0.441   |
| Recent influenza vaccination | 5 (45.5%)    | 47 (28.1%)         | 0.303   |
| Risk factors (%)         |                  |                    |         |
| BMI kg (±SD)             | 24.9 (20.8–28.2) | 25.5 (23.6–29.7)   | 0.170   |
| Diabetes                 | 1 (9.1%)         | 24 (14.1%)         | 1.000   |
| Hypertension             | 7 (63.6%)        | 58 (34.1%)         | 0.058   |
| Hyperlipidaemia          | 4 (44.4%)        | 30 (17.8%)         | 0.069   |
| Smoking                  |                  |                    | 0.719   |
| Never                    | 4 (36.4%)        | 92 (54.1%)         |         |
| Previous                 | 3 (27.3%)        | 36 (21.2%)         |         |
| Current                  | 2 (18.2%)        | 21 (12.4%)         |         |
| Unknown                  | 2 (18.2%)        | 21 (12.4%)         |         |
| Medical history, %       |                  |                    |         |
| Asthma                   | 0                | 33 (19.4%)         | 0.219   |
| COPD                     | 1 (9.1%)         | 11 (6.5%)          | 0.540   |
| Heart failure            | 2 (18.2%)        | 7 (4.2%)           | 0.098   |
| MI                       | 2 (18.2%)        | 12 (7.1%)          | 0.204   |
| PVD                      | 1 (9.1%)         | 2 (1.2%)           | 0.172   |
| Stroke                   | 2 (18.2%)        | 5 (2.9%)           | 0.060   |
| Laboratory findings      |                  |                    |         |
| Hs-cTnI, median, ng/L (IQR) | 85.0 (62.3–252.3) | 3.7 (2.5–8.7)     | <0.001  |
| Hs-cTnI, mean, ng/L (±SD) | 132.6 (103.2)    | 7.6 (8.6)          | <0.001  |
| NT-proBNP, ng/L (IQR)    | 2760 (1001.8–4886.8) | 143 (55.0–447.5) | <0.001  |
| NT-proBNP, elevated, n (%) | 9 (81.8%)    | 53 (31.2%)         | <0.001  |
| Hs-CRP mg/L (IQR)        | 50.0 (37.0–104.0) | 31.5 (17.0–52.5)  | 0.016   |
| WBC, ×10*9/L (±SD)       | 8.3 (3.3)        | 7.1 (3.5)          | 0.288   |
| Platelets, ×10*9/L (±SD) | 207.2 (46.7)     | 208.8 (73.6)       | 0.943   |
| eGFR, μmol/L (IQR)       | 69.0 (42.0–78.0) | 85.0 (65.0–96.0)   | 0.052   |
| ECG at presentation      |                  |                    |         |
| Heart rate b/min (±SD)   | 95 (24)          | 91 (18)            | 0.517   |
| Atrial fibrillation (%)  | 2 (18.2%)        | 16 (9.4%)          | 0.300   |
| ST-elevation (%)         | 0                | 0                  | 0       |
| ST-depression (%)        | 0                | 8 (4.7%)           | 1.00    |
| LBBB (%)                 | 3 (27.3%)        | 2 (1.2%)           | 0.002   |

Variable with missing values, numbers (elevated/no elevated): heart rate 0/164. BMI, body mass index; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; PVD, peripheral vascular disease; Hs-CRP, high-sensitivity C-reactive protein; WBC, white blood cells; LBBB, left bundle branch block. Bold P-values are significant (P < 0.05).

*P-value: difference between patients with and without elevated hs-cTnI.
### Table 3 Univariate and multivariate Cox regression analyses of factors associated with major adverse cardiovascular events

| Demographics            | Number | Univariate | Multivariate |
|-------------------------|--------|------------|--------------|
|                         | HR     | 95%CI      | P-value      | HR     | 95%CI      | P-value      |
| Sex                     |        |            |              |        |            |              |
| Men                     | 95     | 0.67       | 0.16–2.79    | 0.572  | 1.13       | 0.98–1.29    | 0.085  |
| Women                   | 86     | 1.14       | 1.05–1.23    | <0.002 | 1.13       | 0.98–1.29    | 0.085  |
| Age                     | 181    | 0.93       | 0.72–1.21    | 0.585  | 2.57       | 0.64–10.27   | 0.182  |
| Current infection        |        |            |              |        |            |              |
| Days with symptoms       | 181    | 1.14       | 1.05–1.23    | <0.002 | 1.13       | 0.98–1.29    | 0.085  |
| Recent vaccination       | No     | 129        |              |        |            |              |
|                         | Yes    | 52         | 2.57         | 0.64–10.27 | 0.182   | 1.13         | 0.98–1.29 | 0.085  |
| Risk factors             |        |            |              |        |            |              |
| BMI                      | 181    | 1.00       | 0.86–1.16    | 0.973  | 1.00       | 0.86–1.16    | 0.973  |
| Diabetes                 | No     | 156        | 0.88         | 0.11–7.12 | 0.902   | 1.14         | 0.27–4.78  | 0.856  |
|                         | Yes    | 25         | 0.88         | 0.11–7.12 | 0.902   | 1.14         | 0.27–4.78  | 0.856  |
| Hypertension             | No     | 116        | 1.30         | 0.19–8.95 | 0.655   | 1.30         | 0.19–8.95  | 0.655  |
|                         | Yes    | 65         | 1.30         | 0.19–8.95 | 0.655   | 1.30         | 0.19–8.95  | 0.655  |
| Hyperlipidaemia          | No     | 147        | 0.03         | 0.00–43.83 | 0.354  | 0.03         | 0.00–43.83 | 0.354  |
|                         | Yes    | 34         | 0.88         | 0.11–7.12 | 0.902   | 1.45         | 0.29–7.17  | 0.651  |
| Smoking                  | No     | 119        | 1.00         | 0.86–1.16 | 0.973  | 1.00         | 0.86–1.16  | 0.973  |
|                         | Yes    | 62         | 1.00         | 0.86–1.16 | 0.973  | 1.00         | 0.86–1.16  | 0.973  |
| Medical history          |        |            |              |        |            |              |
| Asthma or COPD           | No     | 142        | 0.03         | 0.00–43.83 | 0.354  | 0.03         | 0.00–43.83 | 0.354  |
|                         | Yes    | 39         | 0.88         | 0.11–7.12 | 0.902   | 1.14         | 0.27–4.78  | 0.856  |
| Heart failure            | No     | 172        | 2.80         | 0.34–22.76 | 0.336  | 1.30         | 0.19–8.95  | 0.655  |
|                         | Yes    | 9          | 2.80         | 0.34–22.76 | 0.336  | 1.30         | 0.19–8.95  | 0.655  |
| MI                       | No     | 167        | 1.00         | 0.86–1.16 | 0.973  | 1.00         | 0.86–1.16  | 0.973  |
|                         | Yes    | 14         | 1.45         | 0.29–7.17 | 0.651   | 1.45         | 0.29–7.17  | 0.651  |
| Stroke                   | No     | 174        | 1.00         | 0.86–1.16 | 0.973  | 1.00         | 0.86–1.16  | 0.973  |
|                         | Yes    | 7          | 3.84         | 0.47–31.22 | 0.208  | 3.84         | 0.47–31.22 | 0.208  |
| Laboratory findings      |        |            |              |        |            |              |
| Troponin I, elevated     | No     | 170        |              |        |            |              |
|                         | Yes    | 11         | 18.29        | 4.57–73.24 | <0.001 | 4.96         | 1.10–22.41 | 0.037  |
| Troponin I, ng/L         | 181    | 1.01       | 1.01–1.02    | <0.001 | 1.01       | 1.01–1.02    | <0.001 |
| NT-proBNP, elevated      | No     | 119        |              |        |            |              |
|                         | Yes    | 62         | 14.21        | 1.75–115.5 | 0.013 | 7.30         | 0.66–9.18  | 0.805  |
| eGFR                     | 181    | 0.94       | 0.91–0.97    | <0.001 | 0.97       | 0.92–1.03    | 0.321  |
| Hs-CRP mg/L              | 181    | 1.01       | 1.00–1.02    | 0.045  | 1.00       | 0.98–1.02    | 0.742  |
| WBC, ×10^9/L             | 181    | 1.12       | 1.01–1.25    | 0.039  | 1.32       | 0.98–1.79    | 0.068  |
| Platelets, ×10^9/L       | 181    | 1.01       | 1.00–1.01    | 0.136  | 1.01       | 1.00–1.01    | 0.136  |
| ECG at presentation      |        |            |              |        |            |              |
| Atrial fibrillation      | No     | 163        |              |        |            |              |
|                         | Yes    | 18         | 3.17         | 0.64–15.73 | 0.157  | 3.17         | 0.64–15.73 | 0.157  |
| ST-depression            | No     | 173        |              |        |            |              |
|                         | Yes    | 8          | 0.03         | 0.12–85.24 | 0.685  | 0.03         | 0.12–85.24 | 0.685  |
| LBBB                     | No     | 176        |              |        |            |              |
|                         | Yes    | 5          | 6.01         | 0.74–48.88 | 0.094  | 6.01         | 0.74–48.88 | 0.094  |

BMI: body mass index; ECG, electrocardiogram; Hs-CRP, high-sensitivity C-reactive protein; LBBB, left bundle branch block; WBC, white blood cells.

Bold P-values are significant (P < 0.05).

*Multivariate analysis: Cox regression analysis including all factors P < 0.05 in the univariate analysis.
Outcome in patients with influenza

At 1-year follow-up, eight (4%) of the patients with influenza had experienced MACE; including four with (36%) and four (2%) without elevated hs-cTnI (P < 0.01). All four patients with influenza and elevated hs-cTnI who experienced MACE died, one of a cardiovascular cause (stroke) and three of non-cardiovascular causes (one each of ileus, acute gastric ulcer, and pulmonary cancer). Of the four patients with influenza but without elevated hs-cTnI who experienced MACE, one was later admitted with MI, one with stroke, and one with atrial fibrillation, with the fourth dying of pneumonia.

One patient each experienced MACE 11 and 44 days after being diagnosed with influenza, with the remaining events occurring 5–11 months later. No patients were lost to follow-up.

Variables associated with major adverse cardiovascular events in patients diagnosed with influenza

Univariate analysis of variables associated with MACE in patients with influenza infection was older age; hypertension; lower estimated glomerular filtration rate; higher concentrations of hs-cTnI, NT-proBNP, and hs-CRP; and higher WBC counts (Table 3). In multivariable analysis, elevated hs-cTnI was independently associated with MACE (Table 3). The association between elevated hs-cTnI and MACE was also evaluated by log-rank test and a Kaplan–Meier curve, P < 0.001.

Patients without influenza

The prevalence of elevated hs-cTnI was 11 and 13% experienced MACE in the non-influenza group. A total of 123 patients (44%) were hospitalized after ED evaluation, of which 25 patients had elevated hs-cTnI and 98 patients had not. Diseases of the respiratory system were the most common discharge diagnoses (56.1%), followed by diseases of the circulatory system (12.2%), diseases of the genitourinary system (11.4%), and certain infectious and parasitic diseases (10.6%). An additional 12 patients were admitted within 30 days, and their discharge diagnoses were also mainly among the diseases of respiratory system (see Supplementary material online, Table S1). The majority of patients without admission to hospital received unspecified diagnoses at the EDs. In univariate analysis, elevated hs-cTnI was associated with outcome: HR 3.43 (95% CI 1.63–7.119), P < 0.001.

Discussion

In this prospective cohort study assessing the prevalence and prognostic value of elevated hs-cTnI in an unselected population of patients with laboratory-confirmed influenza infection patients were included during three influenza seasons. The prevalence of elevated hs-cTnI in our cohort of 181 patients with documented influenza was 6%, much lower than in two recent retrospective studies, which found that the prevalence rates of elevated hs-cTnI in patients with influenza were 31.8% 23 47.7%, 24 and 65.5%. 25 However, unlike the present prospective study, the two previous retrospective reports calculated the prevalence of elevated hs-cTnI in selected individuals in whom hs-cTnI had been measured, thus increasing the likelihood of inclusion bias. Furthermore, the median age of patients in the present study was 55 years, and most had not been admitted to hospital. By contrast, the median age of the patients in the previous studies was between 66 and 80 years, and a large proportion of patients had been admitted to hospital, implying more severe disease. 24,25 Additionally, in the recent prospective study 12.4% were admitted to the intensive care unit. 24 The prevalence rates of elevated hs-cTnI in patients aged ≥65 years in those admitted to hospital in the present study, however, were 10 and 14%, respectively.

During the 1-year follow-up period, 4% of the patients in this cohort experienced at least one adverse event. Half of these patients experienced a cardiovascular event (MI, stroke, atrial fibrillation, or death from stroke) and the rest died of non-cardiovascular causes. Multivariate analysis showed that elevated hs-cTnI was independently associated with MACE. However, due to the low number of events, this finding must be interpreted with caution.

Several studies have demonstrated an increased risk of cardiovascular events following infection with influenza virus. 5,5–9,15 The pathophysiological mechanisms underlying triggering of cardiovascular complications can include increased coronary and systemic inflammatory activity, 28 release of cytokines and interleukins that may lead to plaque destabilization, 29 plaque rupture, 29 increased procoagulant conditions including triggering of the coagulation cascade, 28–30 sympathetic activation with subsequent effects on vascular tone with vasoconstriction, 30 endothelial dysfunction, 28,30 and inadequate coronary artery blood flow due to increased metabolic demand, with fever, tachycardia, reduced oxygen saturation, and hypotension. 28,30

In the present study, half of the major adverse events were cardiovascular and the rest were non-cardiovascular. Our univariate and multivariate analyses indicate that older age, elevated hs-cTnI, lower eGFR, and higher inflammatory markers to be associated with MACE. We hypothesize that an elevated hs-cTnI in an older individual during influenza infection is a sign of frailty that may serve as a prognosticator for poor prognosis.

Although none of the patients with influenza in the present study experienced myocarditis, four patients with elevated hs-cTnI at the time of study inclusion were not hospitalized and review of their inpatient and outpatient medical charts found no further assessments. All were men aged between 27 and 74 years of age; all had ECGs showing normofrequent sinus rhythm without ST-elevation or depression. However, one individual had a left branch bundle block. Thus, the mechanism underlying hs-cTn elevation in these patients could not be determined.

The control group, consisting of patients with influenza-like symptoms but negative PCR test for influenza, had at baseline higher levels of NT-proBNP and inflammatory biomarkers compared with the influenza group. The older age and more prevalent heart failure in the control group may contribute to the difference in NT-proBNP levels. Furthermore, the control group was more often than the influenza group affected of bacterial infections resulting in pneumonia and sepsis and this may contribute to the higher levels of inflammatory markers.

Increased levels of hs-cTn hold prognostic value in hospitalized influenza patients, 24,25 in unselected patients presenting to the ED with symptoms suggestive of acute coronary syndrome 16 and inpatients at cardiac wards. 32 Patients with evidence of myocardial injury or Type...
and significant short-term effects. Differences in composition of the population and that the risk of all-cause death, cardiovascular death, and hospitalization due to heart failure increases with biomarker levels.

Elevated hs-cTnI in patients with influenza in the present study was associated with adverse long-term but not short-term prognosis. This finding, contrasts observations from previous studies indicating differences in composition of cohorts, number of inpatients, and the severity of influenza disease may contribute to the discrepancy. Patients with elevated hs-cTnI were older, had more often elevated NT-proBNP and hs-CRP than patients without elevated hs-cTnI. Cardiovascular risk factors such as sex, smoking, previous cardiovascular disease, and previous heart failure were however similar between groups. This implies that elevated hs-cTnI, as a marker of myocardial injury, in patients with influenza carries an independent prognostic value.

Clinical implications
The present study found that the prevalence of elevated hs-cTnI in an unselected population with influenza infection is low. An elevated hs-cTnI accompanying influenza was associated with poor prognosis. Most of the patients with elevated hs-cTnI also needed in-hospital care. An elevated hs-cTnI in an older individual during influenza may therefore be used as a sign of frailty and poor prognosis.

Strengths and limitations
The strengths of the present study are its prospective design with patients included during three influenza seasons, the large number of patients, the broad inclusion criteria, and the use of an hs-cTnI assay. The inclusion of consecutive patients makes the study more universal and the results more generalizable.

One limitation is that, for ethical reasons, the most seriously ill patients seeking care could not be included. Furthermore, patients with obvious ongoing symptoms, indicating an acute coronary syndrome, pulmonary oedema, severe arrhythmia, or acute stroke were excluded. These findings therefore represent hs-cTnI concentrations in patients with influenza-like symptoms. Furthermore, since the study had broad inclusion criteria and exclusion criteria was few, this allowed patients with another clinical conditions to be included, in whom hs-cTnI may be elevated, i.e. end stage renal disease, severe hypertension, anaemia, stress cardiomyopathy, chronic obstructive pulmonary disease, heart failure, pulmonary embolism, severe sepsis, and massive rhabdomyolysis. However, we were able to identify most of these conditions using baseline data and review of medical charts.

The event rate was low and all multivariate analyses must therefore be interpreted with caution. In our multivariable Cox regression model seven factors, univariably associated with MACE, were assessed. This may be considered too many when the number of events is small. Several different procedures, including Cox regression stepwise forward and backward analyses and log-rank test, illustrated by the Kaplan–Meier curve, were used to ascertain the results further.

Conclusion
This study showed that in a consecutive cohort of unselected patients with influenza-like symptoms seeking medical care at Swedish emergency departments, the prevalence of elevated hs-cTnI is low. Individuals with influenza and elevated hs-cTnI seemed to have a poorer prognosis than those with influenza and non-elevated hs-cTnI.

Lead author biography
Anna M Nordenskjöld (MD, PhD) work as a senior consultant in the cardiology department at Örebro University Hospital, Sweden, and is affiliated to the Faculty of Medicine and Health, Örebro University. She is interested in a wide range of topics and have previously published studies on ischaemic heart disease, myocardial infarction with non-obstructive coronary arteries, biomarkers, and the association between affective disorder and cardiovascular disease.

Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.

Supplementary material
Supplementary material is available at European Heart Journal Open online.
Funding
This study was supported by grants from the Region Örebro County Council Research Committee (OPLL 762511, OLL 935107, OLL 939142).

Conflict of interest: O.F. has received an unrestricted research grant from Sanofi Pasteur. A.M.N., S.A., N.J., and E.S. have no conflicts of interest.

References
1. WHO. Influenza (Seasonal). fact sheet. http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). 2018.
2. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio Halvorsen SR, Canty MJ, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newbury JK, Virmani R, Vranic P, Cutlip D, Gobin NM, Smith J, Mahmud SM, Van Aalst R, Thommes EW, Neupane N, Lee JKH, Cao X, Fung E. Conflict of interest:
3. Funding
4. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004–2015. Clin Infect Dis 2018; 67:8–17.
5. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simon A, Sniezka M, Zahradas J, Gubdub Y. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018; 378:345–353.
6. Ludwig A, Lucero-Obusan C, Schulteis HP, Seggewis H, Tavazzi L, Thieme G, Yilmaz A, Charron P, Elliott PM. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiac working group on myocardial and pericardial diseases. Eur Heart J 2013; 34:2636–2648. 2648a–2648d.
7. Kindermann I, Barth C, Mahfoud F, Ukenu C, Lenski M, Yilmaz A, Klingel K, Kandolf R, Sechtem U, Cooper LT, Böhmer M. Update on myocarditis. J Am Coll Cardiol 2012; 59:779–872.
8. Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: a systematic review. Int J Cardiol 2013; 167:2397–2403.
9. Chair SY, Cheng HY, Choi KC, Siow EKC, Cao X, Fung E. High-sensitivity troponins for outcome prediction during H1N1 influenza infection. Eur Heart J 2019; 40:237–269.
10. Fagnoul D, Pasquier P, Bodson L, Ortiz JA, Vincent JL. Acute myocardial dys-function during H1N1 influenza infection. J Crit Care 2013; 28:321–327.
11. To T, Akamatsu K, Fujita S, Kanazaki Y, Ukimura A, Hoshiga M. Transient depression of myocardial function after influenza infection: a study of echocardiographic tissue imaging. PLoS One 2019; 14:e0236866.
12. Lippi G, Sanchis-Gomar F. Cardiac troponin elevation in patients with influenza viruses. Biomed J 2021; 44:183–189.
13. Pizzini A, Burkert F, Theur I, Weiss G, Dellmann-Weiler R. Prognostic impact of high sensitive troponin T in patients with influenza virus infection: a retrospective analysis. Heart Lung 2020; 49:105–109.
14. Basso L, Klersy C, Beretta GS, Valignini M, Valotta A, Gabutti L, Bruna RD, Pagnamenta A, Tersalvi G, Ruinelli L, Arteo A, Sarotenere G, Juni P, Pedrazzini GB. Comparative frequency and prognostic impact of myocardial injury in hospitalized patients with COVID-19 and influenza. Eur Heart J Open 2021; 5:eoa025.
15. Sharma T, Horwood C, Chua A, Hakendorff P, Thompson C. Prognostic impact of high sensitive troponin in predicting 30-day mortality among patients admitted to hospital with influenza. Int J Cardiol Heart Rhythm 2021; 163:1189–1194.
16. Corrales-Medina VF, Suh KN, Rose G, Chirinos JA, Doucette S, Cameron DW, Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction in Denmark 2010 to 2016. Euro Surveill 2013; 2:2011794.
17. Oldroyd KG, Motovska Z, Erglis A, Moer R, Hlinomaz O, Jakobsen L, Engstrøm T, Jensen LO, Fallesen CO, Jensen SE, Angerós O, Calais F, Kåreng A, Lauermann J, Mokriari A, Nilsson J, Persson J, Stalpy B, Islam A, Aham K, Malik F, Choudhury S, Collier T, Pocock SJ, Fernow J. Influenza infection after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation 2021; 144:1476–1484.
18. Thygessen K, Alpert JS, Jaffe AS, Chatman BR, Bab J, Morrow DA, White HD, Thygessen K, Alpert JS, Jaffe AS, Chatman BR, Bab J, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hammad CW, De Caterina R, Januzzi JL, Apple FS, Alonso Garcia MA, Underwood SR, Canty MJ, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newbury JK, Virmani R, Vranic P, Cutlip D, Gobin NM, Smith J, Mahmud SM, Van Aalst R, Thommes EW, Neupane N, Lee JKH, Cao X, Fung E. Conflict of interest:
19. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004–2015. Clin Infect Dis 2018; 67:8–17.
20. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simon A, Sniezka M, Zahradas J, Gubdub Y. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018; 378:345–353.
21. Ludwig A, Lucero-Obusan C, Schirmer P, Winston C, Holodniy M. Acute myocardial infarction after laboratory-confirmed influenza virus infection among U.S. Veterans, 2010–2012. BMC Cardiovasc Disord 2015; 15:109.
22. Mohammad MA, Than J, Koul S, Rylance R, Bergh C, Erlinge D, Fröbert O. Association of acute myocardial infarction with influenza: a nationwide observational study. PLoS One 2020; 15:e0236686.
23. Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J 2018; 51:1701794.
24. Warren-Gash C, Hayward AC, Hemingway H, Danaxas S, Thomas SL, Tinimis AD, Whitaker H, Smeeth L. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2020; 206:1652–1659.
25. Young-Xu Y, Smith J, Mahmud SM, Van Aalst R, Thomsen EW, Neupane N, Lee JKH, Chit A. Laboratory.confirmed influenza infection and acute myocardial infarction among United States senior veterans. PLoS One 2020; 15:e0243248.
26. Oihlajärvi J, Warren-Gash C, Blackburn R, Molbak K, Vahteristo P, Nielsen J, Emborg H-D. Acute myocardial infarctions and stroke triggered by laboratory-confirmed respiratory infections in Denmark 2010 to 2016. Euro Surveill 2020; 25:1900199.
27. Tripathi B, Kumar V, Kalra A, Gupta T, Sawant AC, Sharma P, Arora S, Panwar MS, Gopalan R, Deshmukh A, Pershad A, Gulati M, Bhatt DL. Influence of influenza infection on in-hospital acute myocardial infarction outcomes. Am J Cardiol 2020; 130:7–14.
28. Veghonga P, Kitkungvan D, Madij M, Charitaks K, Anderson HV, Arain S, Balan P, Smiling RW, Dholbe A. Outcome of acute myocardial infarction in patients with influenza and other viral respiratory infections. Am J Med 2019; 137:1173–1181.
29. Frobert O, Gotzb erg M, Erlinge D, Aiktar Z, Christiansen EH, Plachtye CR, Oldroyd KG, Motoviska Z, Engls A, Moer R, Hinnozam O, Jakobsen L, Engstrom T, Jensen LO, Fallesen CO, Jensen SE, Angerós O, Calais F, Kåreng A, Lauermann J, Mokriari A, Nilsson J, Persson J, Stalpy B, Islam A, Aham K, Malik F, Choudhury S, Collier T, Pocock SJ, Fernow J. Influenza infection after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation 2021; 144:1476–1484.